WB result of MMP14 Recombinant Rabbit mAb
Primary antibody: MMP14 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: MCF7 whole cell lysate 20 µg
Lane 2: HT-1080 whole cell lysate 20 µg
Lane 3: BxPC-3 whole cell lysate 20 µg
Lane 4: U-87 MG whole cell lysate 20 µg
Lane 5: A431 whole cell lysate 20 µg
Negative control: MCF7 whole cell lysate
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 66 kDa
Observed MW: 58 kDa
MMP14 Recombinant Rabbit mAb (S-2922-69)
MMP14 Recombinant Rabbit mAb (S-2922-69)
Price:
Regular price
$131.00 SGD
Regular price
Sale price
$131.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | MMP14 |
| Synonyms | Matrix metalloproteinase-14; MMP-14; MMP-X1; Membrane-type matrix metalloproteinase 1 (MT-MMP 1; MTMMP1); Membrane-type-1 matrix metalloproteinase (MT1-MMP; MT1MMP) |
| Immunogen | Synthetic Peptide |
| Location | Cytoplasm, Cell membrane |
| Accession | P50281 |
| Clone Number | S-2922-69 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu |
| Positive Sample | HT-1080, BxPC-3, U-87 MG, A431 |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
Background
Matrix metalloproteinase-14 (MMP14, MT1-MMP) is a trans-membrane, zinc-dependent endopeptidase that serves as a master regulator of pericellular proteolysis by cleaving virtually all extracellular-matrix proteins (collagens, laminins, fibronectin, proteoglycans), activating pro-MMP2 and pro-MMP13, shedding cell-surface receptors and adhesion molecules, and thereby governing development, angiogenesis, wound repair, adipogenesis and alveolarization, while its chronic over-expression—driven by TGF-β/SMAD, HIF-2α/Sp1 or EGF signalling and restrained by TIMP-2, microRNAs and promoter methylation—promotes tumour invasion, metastasis, fibrosis and obesity, making it a key therapeutic target in cancer, Graves’ orbitopathy, BPD and other ECM-related disorders.
Picture
Picture
Western Blot
